Paul Grint, MD
Acting CMO & Medical Board Chair
Paul is a seasoned CEO with over two decades of experience in biologics and small-molecule research and development. He has successfully commercialized products in infectious diseases, immunology, and oncology. With senior management roles at renowned companies, Paul brings strategic expertise to his current positions as executive chairman of Cardea Bio and board member at Amplyx Pharmaceuticals, Inhibikase Therapeutics, and Synedgen. He holds a medical degree in pathology, is a Fellow of the Royal College of Pathologists, and serves as Chair of Targazyme’s Medical Advisory Board/Acting CMO.